Salix Pharma Beats Street EPS; Strong Revenue Growth Driven By Rx

Loading...

Sign in or sign up now!
Alert icon
Upgrade to the latest Flash Player for improved playback performance. Upgrade now or more info.
97 views
Loading...
Alert icon
Sign in or sign up now!
Alert icon

Uploaded by on Feb 28, 2011

Salix Pharmaceuticals (NASDAQ:SLXP) reported Q4 EPS of $0.66, which came in ahead of consensus estimates for $0.49.

Total product revenue for the quarter grew 69% year-over-year to $118.5 million, while total product revenue for the full year rose 45% from 2009 to $337 million.

The company's attributed its 2010 revenue increases to the sales of its drugs, XIFAXAN and APRISO. Q4 performance was driven by strong prescription growth from both MOVIPREP and APRISO.

Salix anticipates 2011 revenues of approximately $520 million, or 54% growth over 2010's revenue.

  • likes, 0 dislikes

Link to this comment:

Share to:
see all

All Comments (0)

Sign In or Sign Up now to post a comment!
Loading...

Alert icon
0 / 00Unsaved Playlist Return to active list
    1. Your queue is empty. Add videos to your queue using this button:
      or sign in to load a different list.
    Loading...Loading...Saving...
    • Clear all videos from this list
    • Learn more